Dual blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) pathways synergistically inhibits rhabdomyosarcoma cell growth in vitro and in vivo

PURPOSE: To provide rationale for using PI3K and/or MAPK pathway inhibitors to treat rhabdomyosarcomas (RMS), a major cause of pediatric/adolescent cancer deaths. EXPERIMENTAL DESIGN: The prevalence of PI3K/MAPK pathway activation in RMS clinical samples was assessed using immunohistochemistry. Comp...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Renshaw, Jane, Taylor, Kathryn R., Bishop, Ryan, Valenti, Melanie, De Haven Brandon, Alexis, Gowan, Sharon, Eccles, Suzanne A., Ruddle, Ruth R., Johnson, Louise D., Raynaud, Florence I., Selfe, Joanna L., Thway, Khin, Pietsch, Torsten, Pearson, Andrew D., Shipley, Janet
Formato: Artigo
Idioma:Inglês
Publicado em: 2013
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3818134/
https://ncbi.nlm.nih.gov/pubmed/23918606
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-13-0850
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados